Belldegrun Arie 4

What Happened Arie Belldegrun, a director of Allogene Therapeutics (ALLO), received two equity awards on February 2, 2026 totaling 1,192,946 derivative shares: 929,913 and 263,033 shares respectively. Both awards were reported as acquisitions at $0.00 per share (i.e., granted awards/derivatives rather than open-market purchases). One award is documented as Restricted Stock Units (RSUs) that vest in four equal annual installments; the other award carries a vesting schedule of 25% after one year (Feb 2, 2027) with the remainder vesting in 36 equal monthly installments.

Key Details

• Transaction date: February 2, 2026; Filing date: February 4, 2026 (appears timely).
• Awards: 929,913 derivative shares and 263,033 derivative shares; total 1,192,946 shares; price reported $0.00 (grants).
• Vesting: RSUs vest in 4 equal annual installments starting Feb 2, 2026 (footnote F6). The other award vests 25% on Feb 2, 2027, then monthly over 36 months (footnote F5).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Ownership notes: Some shares are held via trusts and Vida Ventures entities; the filer disclaims beneficial ownership of certain Vida-held shares except for any pecuniary interest (footnotes F1–F4).
• Transaction type: Award/Grant (code A); derivative securities (not an immediate cash purchase or sale).

Context

• Grants at $0.00 are standard equity compensation and do not represent an open-market buy or sell. Vesting is service-based, so the awards only convert to actual shares as they vest.
• RSUs typically convert to one share per unit at vesting; the other award’s vest schedule resembles a time-based option/award. These awards do not by themselves indicate buying/selling sentiment but reflect compensation/retention.
• The reporting person has connections to entities (Vida Ventures and family trusts) referenced in the filing; some holdings are held indirectly and may be disclaimed for beneficial ownership purposes.